Avalyn Pharma
Avalyn is developing inhaled therapies for rare respiratory diseases, aiming to improve treatment efficacy and safety. The company is focused on innovative formulations of existing medicines to target pulmonary fibrosis and interstitial lung diseases.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company's approach focuses on delivering inhaled formulations of established medicines directly to lung tissue to potentially enhance efficacy and reduce systemic side effects. Its pipeline includes two clinical-stage programs, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), as well as a preclinical program, AP03, a fixed-dose combination of both agents.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Avalyn Pharma.
Avalyn Pharma
Aug 5, 2025